NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and secondary brain tumors. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. NeOnc Technologies Holdings, Inc. was incorporated in 2005 and is headquartered in Calabasas, California.
Metrics to compare | NTHI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNTHIPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.8x | −0.2x | −0.5x | |
PEG Ratio | 0.02 | 0.00 | 0.00 | |
Price/Book | −9.9x | 1.1x | 2.6x | |
Price / LTM Sales | 1,948.2x | 4.5x | 3.3x | |
Upside (Analyst Target) | - | 51.3% | 38.7% | |
Fair Value Upside | Unlock | −1.6% | 5.0% | Unlock |